Publications and communications of Céline GREGOIRE

El Moussaoui, M., Desmecht, S., Lambert, N., Maes, N., Braghini, J., MARECHAL, N., Quintana, C., BRIQUET, K., Gofflot, S., Toussaint, F., Hayette, M.-P., Vermeersch, P., Lutteri, L., GREGOIRE, C., Beguin, Y., Rahmouni, S., Moutschen, M., Desmecht, D., & Darcis, G. (2023). Cluster Analysis Identifies Distinct Patterns of T-Cell and Humoral Immune Responses Evolution Following a Third Dose of SARS-CoV-2 Vaccine in People Living with HIV. Viruses, 15, 1435. doi:10.3390/v15071435

El Moussaoui, M., Desmecht, S., Tashkeev, A., Lambert, N., Maes, N., Braghini, J., MARECHAL, N., Quintana, C., BRIQUET, K., Gofflot, S., TOUSSAINT, F., Hayette, M.-P., Vermeersch, P., Lutteri, L., Grégoire, C., Beguin, Y., Rahmouni, S., Moutschen, M., Desmecht, D., & Darcis, G. (05 September 2022). Reduced T-cell response following a third dose of SARS-CoV-2 vaccine in infection-naïve people living with HIV. Journal of Infection, 85, 751-755. doi:10.1016/j.jinf.2022.09.006

GREGOIRE, C.* , LAYIOS, N.* , LAMBERMONT, B., LECHANTEUR, C., BRIQUET, A., Bettonville, V., BAUDOUX, E., THYS, M., Dardenne, N., Misset, B.* , & BEGUIN, Y.*. (04 July 2022). Bone Marrow-Derived Mesenchymal Stromal Cell Therapy in Severe COVID-19: Preliminary Results of a Phase I/II Clinical Trial. Frontiers in Immunology, 13, 932360. doi:10.3389/fimmu.2022.932360
* These authors have contributed equally to this work.

El Moussaoui, M., Maes, N., Hong, S. L., Lambert, N., Gofflot, S., DELLOT, P., Belhadj, Y., Huynen, P., Hayette, M.-P., Meex, C., Bontems, S., Defêche, J., Godderis, L., Molenberghs, G., Meuris, C., Artesi, M., Durkin, K., Rahmouni, S., GREGOIRE, C., ... DARCIS, G. (14 June 2022). Evaluation of Screening Program and Phylogenetic Analysis of SARS-CoV-2 Infections among Hospital Healthcare Workers in Liège, Belgium. Viruses, 14 (6), 1302. doi:10.3390/v14061302

GREGOIRE, C.* , HUYNEN, P.* , Gofflot, S., Seidel, L., Maes, N., VRANKEN, L., DELCOUR, S., MOUTSCHEN, M., HAYETTE, M.-P., KOLH, P., MELIN, P., & BEGUIN, Y. (13 June 2022). Predictive factors for the presence and long-term persistence of SARS-CoV-2 antibodies in healthcare and university workers. Scientific Reports, 12, 9790. doi:10.1038/s41598-022-13450-4
* These authors have contributed equally to this work.

Kegyes, D.* , Constantinescu, C.* , Vrancken, L., Rasche, L., Grégoire, C., Tigu, B., Gulei, D., Dima, D., Tanase, A., Einsele, H., Ciurea, S., Tomuleasa, C., & Caers, J. (07 June 2022). Patient selection for CAR T or BiTE therapy in multiple myeloma: Which treatment for each patient? Journal of Hematology and Oncology, 15 (1), 78. doi:10.1186/s13045-022-01296-2
* These authors have contributed equally to this work.

GREGOIRE, C., SERVAIS, S., WILLEMS, E., BAUDOUX, E., LECHANTEUR, C., BRIQUET, A., Bettonville, V., DETRY, O., ERPICUM, P., JOURET, F., LOUIS, E., BARON, F., & BEGUIN, Y. (April 2022). Immunothérapie cellulaire au CHU de Liège : avancées, défis et perspectives. Revue Médicale de Liège, 77 (4), 206-211.

HUYNEN, P.* , GREGOIRE, C.* , GOFFLOT, S., SEIDEL, L., MAES, N., VRANKEN, L., DELCOUR, S., MOUTSCHEN, M., HAYETTE, M.-P., KOLH, P., MELIN, P., & BEGUIN, Y. (25 March 2022). Long-term longitudinal evaluation of the prevalence of SARS-CoV-2 antibodies in healthcare and university workers. Scientific Reports, 12 (1), 5156. doi:10.1038/s41598-022-09215-8
* These authors have contributed equally to this work.

Massart, N., Maxime, V., Fillatre, P., Razazi, K., Ferré, A., Moine, P., Legay, F., Voiriot, G., Amara, M., Santi, F., Nseir, S., Marque-Juillet, S., Bounab, R., Barbarot, N., Bruneel, F., Luyt, C.-E., the COVID ICU Bacteremia Study Group on behalf of the COVID-ICU Investigators, KISOKA, G. (Other coll.), GREGOIRE, C. (Other coll.), & Lambermont, B. (Other coll.). (January 2022). Correction to: Characteristics and prognosis of bloodstream infection in patients with COVID-19 admitted in the ICU: an ancillary study of the COVID-ICU study (Annals of Intensive Care, (2021), 11, 1, (183), 10.1186/s13613-021-00971-w). Annals of Intensive Care, 12 (1). doi:10.1186/s13613-022-00979-w

COVID-ICU group, for the REVA network, COVID-ICU investigators, KISOKA, G., GREGOIRE, C., & LAMBERMONT, B. (08 December 2021). Benefits and risks of noninvasive oxygenation strategy in COVID-19: a multicenter, prospective cohort study (COVID-ICU) in 137 hospitals. Critical Care, 25 (1), 421. doi:10.1186/s13054-021-03784-2

LAMBERMONT, B., COVID-ICU Group on behalf of the REVA Network and the COVID-ICU Investigators, KISOKA, G., & Grégoire, C. (2021). Clinical characteristics and day-90 outcomes of 4244 ctritically ill adults with COVID-19: a prospective cohort study. Intensive Care Medicine. doi:10.1007/s00134-020-06294-x

Ritacco, C.* , Ehx, G.* , GREGOIRE, C., Daulne, C., WILLEMS, E., SERVAIS, S., BEGUIN, Y., & Baron, F. (2021). High proportion of terminally-differentiated regulatory T cells after allogeneic hematopoietic stem cell transplantation. Bone Marrow Transplantation, 56, 1828-1841. doi:10.1038/s41409-021-01221-0
* These authors have contributed equally to this work.

Delens, L., Ehx, G., SOMJA, J., Vrancken, L., Belle, L., SEIDEL, L., Grégoire, C., Fransolet, G., Ritacco, C., Hannon, M., DUBOIS, S., Beguin, Y., Baron, F., & Servais, S. (2019). In Vitro Th17-Polarized Human CD4(+) T Cells Exacerbate Xenogeneic Graft-versus-Host Disease. Biology of Blood and Marrow Transplantation, 25, 204-215. doi:10.1016/j.bbmt.2018.10.007

Grégoire, C., Ritacco, C., Hannon, M., SEIDEL, L., Delens, L., Belle, L., DUBOIS, S., Veriter, S., LECHANTEUR, C., BRIQUET, A., Servais, S., Ehx, G., Beguin, Y., & Baron, F. (2019). Comparison of Mesenchymal Stromal Cells From Different Origins for the Treatment of Graft-vs.-Host-Disease in a Humanized Mouse Model. Frontiers in Immunology, 10, 619. doi:10.3389/fimmu.2019.00619

GREGOIRE, C., DETRY, O., Jouret, F., BRIQUET, A., LECHANTEUR, C., BAUDOUX, E., Beguin, Y., & GIET, O. (2017). The use of mesenchymal stromal cells in solid organ transplantation. In The Biology and Therapeutic Application of Mesenchymal Cells (pp. 825-835). Hoboken, United States: John Willey & Sons, Inc.

GREGOIRE, C., LECHANTEUR, C., BRIQUET, A., BAUDOUX, E., BARON, F., LOUIS, E., & BEGUIN, Y. (2017). Review article: mesenchymal stromal cell therapy for inflammatory bowel diseases. Alimentary Pharmacology and Therapeutics, 45, 205-221. doi:10.1111/apt.13864

GREGOIRE, C., Louis, E., BRIQUET, A., LECHANTEUR, C., BAUDOUX, E., GIET, O., Beguin, Y., & BARON, F. (2017). The role of mesenchymal stromal cells in the treatment of ulcerative colitis and Crohn’s disease. In The Biology and Therapeutic Application of Mesenchymal Cells (pp. 730-753). Hoboken, United States: John Wiley & Sons, Inc.

Grégoire, C., GUIOT, J., Vertenoeil, G., WILLEMS, E., HAFRAOUI, K., CORHAY, J.-L., LOUIS, R., & BEGUIN, Y. (February 2016). Yellow nail syndrome after allogeneic haematopoietic stem cell transplantation in two patients with multiple myeloma. Acta Clinica Belgica, 71, 428-430. doi:10.1080/17843286.2015.1122872

SERVAIS, S., GREGOIRE, C., BARON, F., WILLEMS, E., BRIQUET, A., BAUDOUX, E., DELLOYE, O., GIET, O., LECHANTEUR, C., & BEGUIN, Y. (2016). Multipotent mesenchymal stromal cell therapy for steroid-refractory acute graft-versus-host disease after allogeneic stem cell transplantation. Belgian Journal of Hematology, 7, 229-235.

Rowart, P., ERPICUM, P., Detry, O., WEEKERS, L., Grégoire, C., LECHANTEUR, C., BRIQUET, A., Beguin, Y., Krzesinski, J.-M., & Jouret, F. (2015). Mesenchymal Stromal Cell Therapy in Ischemia/Reperfusion Injury. Journal of Immunology Research, 602597. doi:10.1155/2015/602597

DETRY, O., JOURET, F., VANDERMEULEN, M., ERPICUM, P., Delens, L., GREGOIRE, C., BRIQUET, A., WEEKERS, L., BAUDOUX, E., LECHANTEUR, C., & BEGUIN, Y. (December 2014). Cellules stromales mésenchymateuses et transplantation d'organes. Revue Médicale de Liège, 69, 53-56.

VANDERMEULEN, M., GREGOIRE, C., BRIQUET, A., LECHANTEUR, C., BEGUIN, Y., & DETRY, O. (2014). Rationale for the potential use of mesenchymal stromal cells in liver transplantation. World Journal of Gastroenterology, 20 (44), 16418-32. doi:10.3748/wjg.v20.i44.16418